PaclitaxelRecent, repeatedEvidence- NCT07926048 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Paclitaxel” · registered Oct 2026
- NCT07743164 · Merck & Co., Inc · Phase 3 · live · comparator · “Paclitaxel” · registered Jul 2026
- NCT07714668 · CSPC Pharmaceutical Group Limited · Phase 2 · live · comparator · “paclitaxel, carboplatin, bevacizumab” · registered Jul 2026
- NCT07684612 · GlaxoSmithKline · Phase 3 · live · comparator · “Paclitaxel” · registered Jun 2026
- NCT07604766 · Genmab · Phase 3 · live · comparator · “Paclitaxel” · registered May 2026
| Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed | 2129 studies | 2334 studies | standard-care 2 · comparator 28 · background 57 |
BevacizumabRecent, repeatedEvidence- NCT07859215 · Genmab · Phase 3 · live · background · “Bevacizumab” · registered Sep 2026
- NCT07816666 · AstraZeneca · Phase 3 · live · background · “Bevacizumab” · registered Sep 2026
- NCT07797283 · Incyte Corporation · Phase 3 · live · background · “Bevacizumab” · registered Aug 2026
- NCT07776691 · Merck & Co., Inc · Phase 3 · live · background · “Bevacizumab” · registered Aug 2026
- NCT07779538 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · background · “bevacizumab” · registered Aug 2026
| Hoffmann-La Roche48% of its industry studiesUS: Hoffmann-La Roche (FDA 2004) + 6 othersEU: Hoffmann-La Roche (EMA 2005) + 7 others | 1328 studies | 1329 studies | background 33 · comparator 4 |
CarboplatinRecent, repeatedPhase 4 trial recordedEvidence- NCT07743164 · Merck & Co., Inc · Phase 3 · live · comparator · “Carboplatin” · registered Jul 2026
- NCT07714668 · CSPC Pharmaceutical Group Limited · Phase 2 · live · comparator · “paclitaxel, carboplatin, bevacizumab” · registered Jul 2026
- NCT07684612 · GlaxoSmithKline · Phase 3 · live · comparator · “Carboplatin” · registered Jun 2026
- NCT07564141 · Genmab · Phase 3 · live · comparator · “Carboplatin” · registered Apr 2026
- NCT07213804 · Eli Lilly and Company · Phase 3 · live · comparator · “Carboplatin” · registered Oct 2025
| Eli Lilly and Company16% of its industry studies | 1216 studies | 1219 studies | comparator 7 · background 46 · standard-care 2 |
liposomal doxorubicinRecent, repeatedEvidence- NCT07926048 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Liposomal Doxorubicin” · registered Oct 2026
- NCT07743164 · Merck & Co., Inc · Phase 3 · live · comparator · “Pegylated liposomal doxorubicin (PLD)” · registered Jul 2026
- NCT07684612 · GlaxoSmithKline · Phase 3 · live · comparator · “Pegylated liposomal doxorubicin (PLD)” · registered Jun 2026
- NCT07604766 · Genmab · Phase 3 · live · comparator · “Pegylated liposomal doxorubicin (PLD)” · registered May 2026
- NCT07564141 · Genmab · Phase 3 · live · comparator · “PLD” · registered Apr 2026
| Johnson & Johnson21% of its industry studiesEU: Baxter Healthcare Corporation (EMA 1996) + 2 others | 1217 studies | 1015 studies | comparator 21 · background 18 |
GemcitabineRecent, repeatedEvidence- NCT07743164 · Merck & Co., Inc · Phase 3 · live · comparator · “Gemcitabine” · registered Jul 2026
- NCT07684612 · GlaxoSmithKline · Phase 3 · live · comparator · “Gemcitabine” · registered Jun 2026
- NCT07604766 · Genmab · Phase 3 · live · comparator · “Gemcitabine” · registered May 2026
- NCT07564141 · Genmab · Phase 3 · live · comparator · “Gemcitabine” · registered Apr 2026
- NCT07286266 · GlaxoSmithKline · Phase 3 · live · comparator · “Gemcitabine” · registered Dec 2025
| Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed | 812 studies | 711 studies | comparator 11 · background 13 · standard-care 1 |
TopotecanRecent, repeatedEvidence- NCT07926048 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Topotecan” · registered Oct 2026
- NCT07604766 · Genmab · Phase 3 · live · comparator · “Topotecan” · registered May 2026
- NCT07213804 · Eli Lilly and Company · Phase 3 · live · comparator · “Topotecan” · registered Oct 2025
- NCT06855069 · Hansoh Pharmaceutical Group Company Limited · Phase 3 · live · comparator · “Topotecan” · registered Feb 2025
- NCT06828354 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Topotecan Hydrochloride for Injection” · registered Feb 2025
| GlaxoSmithKline55% of its industry studiesUS: off-patent, 4 generics marketedEU: off-patent, 1 generic authorized | 810 studies | 79 studies | comparator 15 · background 3 |
pembrolizumabRecent, repeatedEvidence- NCT07749586 · Arvinas Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Jul 2026
- NCT07286266 · GlaxoSmithKline · Phase 3 · live · comparator · “Pembrolizumab” · registered Dec 2025
- NCT05797168 · AstraZeneca · Phase 2 · live · background · “Pembrolizumab” · registered Feb 2023
- NCT05579366 · Genmab · Phase 2 · live · background · “Pembrolizumab” · registered Oct 2022
- NCT04561362 · BicycleTx Limited · Phase 2 · live · background · “Pembrolizumab” · registered Sep 2020
| Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015) | 44 studies | 66 studies | background 9 · comparator 1 |
FulvestrantRecent, repeatedEvidence- NCT07109726 · Terremoto Biosciences Inc. · Phase 2 · live · background · “Fulvestrant injection” · registered Jul 2025
- NCT06993844 · Ensem Therapeutics · Phase 2 · live · background · “ETX-636 dose escalation in combination with fulvestrant” · registered May 2025
- NCT05768139 · Eli Lilly and Company · Phase 2 · live · background · “Fulvestrant” · registered Mar 2023
- NCT05735080 · Incyclix Bio · Phase 2 · live · background · “Fulvestrant” · registered Feb 2023
- NCT03197584 · ImmunityBio, Inc. · Phase 2 · background · “Fulvestrant” · registered Jun 2017
| AstraZeneca70% of its industry studiesUS: off-patent, 11 generics marketedEU: off-patent, 1 generic authorized | 44 studies | 44 studies | background 5 |
niraparibRecent, repeatedEvidence- NCT06915025 · Imunon · Phase 3 · live · background · “Niraparib” · registered Apr 2025
- NCT06433219 · Merck KGaA, Darmstadt, Germany · Phase 2 · background · “Niraparib” · registered May 2024
- NCT05335993 · CanariaBio Inc. · Phase 2 · live · background · “Niraparib” · registered Feb 2022
- NCT05198804 · K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Phase 2 · background · “Niraparib” · registered Dec 2021
| GlaxoSmithKline53% of its industry studiesUS: GlaxoSmithKline (FDA 2023)EU: GlaxoSmithKline (EMA 2017) | 44 studies | 22 studies | background 4 |
DoxorubicinRecent, repeatedEvidence- NCT06855069 · Hansoh Pharmaceutical Group Company Limited · Phase 3 · live · comparator · “Doxorubicin” · registered Feb 2025
- NCT06751485 · Alphamab Oncology · Phase 3 · live · comparator · “Doxorubicin” · registered Dec 2024
- NCT06394492 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Doxorubicin” · registered Apr 2024
- NCT03804866 · AGC Biologics S.p.A. · Phase 2 · background · “Doxorubicin” · registered Oct 2018
- NCT01358071 · AGC Biologics S.p.A. · Phase 2 · background · “Doxorubicin” · registered May 2011
| Hoffmann-La Roche10% of its industry studiesUS: off-patent, 14 generics marketed | 33 studies | 33 studies | comparator 4 · background 2 |
olaparibRecent, repeatedEvidence- NCT06915025 · Imunon · Phase 3 · live · background · “Olaparib” · registered Apr 2025
- NCT06686030 · Akeso · Phase 2 · live · background · “Olaparib” · registered Nov 2024
- NCT06065059 · Tango Therapeutics, Inc. · Phase 2 · background · “Olaparib” · registered Sep 2023
- NCT04669002 · Ellipses Pharma · Phase 2 · background · “Olaparib tablets” · registered Dec 2020
| AstraZeneca76% of its industry studiesUS: AstraZeneca (FDA 2017)EU: AstraZeneca (EMA 2014) | 33 studies | 22 studies | background 4 |
LetrozoleRecent, repeatedEvidence- NCT06072781 · Verastem, Inc. · Phase 3 · live · comparator · “Letrozole” · registered Oct 2023
- NCT05768139 · Eli Lilly and Company · Phase 2 · live · background · “Letrozole” · registered Mar 2023
- NCT04931342 · Hoffmann-La Roche · Phase 2 · live · background · “Letrozole” · registered Jun 2021
| Novartis52% of its industry studiesUS: off-patent, 6 generics marketed | 22 studies | 33 studies | comparator 1 · background 2 |
palbociclibRecent, repeatedEvidence- NCT06188520 · AstraZeneca · Phase 2 · live · background · “Palbociclib” · registered Dec 2023
- NCT05768139 · Eli Lilly and Company · Phase 2 · live · background · “Palbociclib” · registered Mar 2023
- NCT04931342 · Hoffmann-La Roche · Phase 2 · live · background · “Palbociclib” · registered Jun 2021
| Pfizer81% of its industry studiesUS: Pfizer (FDA 2015)EU: off-patent, 1 generic authorized | 22 studies | 33 studies | background 3 |
abemaciclibRecent, repeatedEvidence- NCT06188520 · AstraZeneca · Phase 2 · live · background · “Abemaciclib” · registered Dec 2023
- NCT05735080 · Incyclix Bio · Phase 2 · live · background · “Abemaciclib” · registered Feb 2023
- NCT04931342 · Hoffmann-La Roche · Phase 2 · live · background · “Abemaciclib” · registered Jun 2021
| Eli Lilly and Company98% of its industry studiesUS: Eli Lilly and Company (FDA 2017)EU: Eli Lilly and Company (EMA 2018) | 22 studies | 33 studies | background 3 |
TemozolomideRecent, repeatedEvidence- NCT07811297 · Advenchen Pharmaceuticals, LLC. · Phase 2 · live · background · “Temozolomide (TMZ)” · registered Aug 2026
- NCT05417594 · AstraZeneca · Phase 2 · live · background · “Temozolomide (TMZ)” · registered May 2022
- NCT04851834 · Xennials Therapeutics Australia Pty Ltd · Phase 2 · background · “Temozolomide” · registered Apr 2021
- NCT02836028 · Pfizer · Phase 2 · background · “Temozolomide” · registered Jul 2016
- NCT01618136 · Eisai Co., Ltd. · Phase 2 · comparator · “E7449 plus TMZ” · registered May 2012
| Merck & Co., Inc23% of its industry studiesUS: off-patent, 7 generics marketedEU: off-patent, 4 generics authorized | 22 studies | 22 studies | background 5 · comparator 1 |
CyclophosphamideRecent, repeatedEvidence- NCT07589543 · Beijing Biotech · Phase 2 · live · background · “Cyclophosphamide” · registered May 2026
- NCT05451849 · TCR2 Therapeutics · Phase 2 · background · “Cyclophosphamide” · registered Jun 2022
- NCT04389229 · immetacyte ltd · Phase 2 · background · “cyclophosphamide” · registered Jan 2020
- NCT03907852 · TCR2 Therapeutics · Phase 2 · live · background · “cyclophosphamide” · registered Apr 2019
- NCT03197584 · ImmunityBio, Inc. · Phase 2 · background · “Cyclophosphamide” · registered Jun 2017
| Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed | 22 studies | 22 studies | background 5 |
fludarabineRecent, repeatedPhase 4 trial recordedEvidence- NCT07589543 · Beijing Biotech · Phase 2 · live · background · “Fludarabine” · registered May 2026
- NCT05451849 · TCR2 Therapeutics · Phase 2 · background · “Fludarabine” · registered Jun 2022
- NCT04389229 · immetacyte ltd · Phase 2 · background · “fludarabine” · registered Jan 2020
- NCT03907852 · TCR2 Therapeutics · Phase 2 · live · background · “fludarabine” · registered Apr 2019
| Beijing Biotech18% of its industry studies | 22 studies | 22 studies | background 4 |
AnastrozoleRecent, repeatedEvidence- NCT06072781 · Verastem, Inc. · Phase 3 · live · comparator · “Anastrozole” · registered Oct 2023
- NCT05768139 · Eli Lilly and Company · Phase 2 · live · background · “Anastrozole” · registered Mar 2023
| AstraZeneca66% of its industry studiesUS: off-patent, 6 generics marketed | 22 studies | 22 studies | comparator 1 · background 1 |
ribociclibRecent, repeatedEvidence- NCT06188520 · AstraZeneca · Phase 2 · live · background · “Ribociclib” · registered Dec 2023
- NCT05768139 · Eli Lilly and Company · Phase 2 · live · background · “Ribociclib” · registered Mar 2023
| Novartis87% of its industry studiesUS: Novartis (FDA 2017)EU: Novartis (EMA 2017) | 22 studies | 22 studies | background 2 |